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Abstract
Background: Congaplex® and Immuplex® are dietary supplements that have been traditionally
used to support immune system function. The purpose of these experiments was to determine
whether Congaplex® and Immuplex® affect immune function using primary and immortalized T
lymphocytes.
Methods: Immortalized CEM and Jurkat T lymphocytes and primary peripheral mononuclear
blood cells (PBMCs) were treated with the aqueous extracts from Congaplex® and Immuplex® to
determine the effects of these products on cytokine production in activated T lymphocytes.
Results: Congaplex® enhanced phytohemagglutinin/phorbol 12-myristate 13-acetate (PHA/PMA)
stimulation of both CEM and Jurkat cells as measured by the production of cytokines, while
Immuplex®  suppressed PHA/PMA-induced production of cytokines, with the exception of
interleukin (IL)-8 which was enhanced by Immuplex®. In vitro treatment of PBMCs from 10 healthy
donors with Congaplex® or Immuplex® decreased PHA-stimulated production of interferon (IFN)-
γ but increased the production of IL-13.
Conclusions: While the effects of Congaplex® and Immuplex® differed in these two models, these
data demonstrate that the aqueous extracts from these two dietary supplements can affect the
inflammatory response of T lymphocytes.
Background
CD4+ T lymphocytes protect the body from infection by
bacteria, viruses and parasites [1,2]. Once activated, T
helper cells in turn activate other immune cells such as
macrophages, B lymphocytes and cytotoxic T lymphocytes
in order to defend the individual against these infections.
Activation of T lymphocytes results in production of a
number of cytokines, many of which are specific for either
Th1 cells, including interferon (IFN)-γ and interleukin
(IL)-2, or Th2 cells, including IL-4, IL-5, IL-6, IL-10 and IL-
13 [3-11].
Inflammation is associated with an increasing number of
chronic diseases, and T lymphocytes are involved in the
mechanisms underlying many of these [12]. Research has
demonstrated that T lymphocytes are involved in a
number of chronic diseases, examples of which are
Crohn's disease [13], psoriasis vulgaris [14] and rheuma-
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toid arthritis [15]. In fact, some of the most successful
medications for these conditions target cytokines that are
produced by T lymphocytes and prevent their action.
The context of T lymphocyte activity is crucial when inter-
preting whether enhancement or suppression of activity
will produce a positive outcome because of the complex-
ity of the role of immune function in infection and
chronic inflammation [16,17]. In theory, optimal
immune function would consist of minimal T cell activity
under healthy conditions and maximal T cell activity at
times of infection or under conditions where the chances
of infection are increased.
Many traditionally medicines have been used to modulate
immune function in an attempt to either aid an individ-
ual's ability to fight off infection [18-21] or to reduce the
chance of disease produced by chronic inflammation [22-
25]. Congaplex® and Immuplex® are products containing a
complex mixture of compounds, many of which have
demonstrated immunomodulatory abilities including
mushrooms [26], buckwheat [27] and carrots [28]. Addi-
tionally, a number of the materials in Congaplex® and
Immuplex®  have traditionally been used to modulate
immune function as part of complementary and alterna-
tive medicinal practices such as alfalfa [29], mushrooms
[26] and glandular materials [30,31].
Traditionally, Congaplex® and Immuplex® have been used
differently, with Immuplex® being used under "healthy"
conditions to support immune function and Congaplex®
being used at the onset of sickness to help support the
immune system in fighting off infection. Although there is
substantial anecdotal evidence to support their effective-
ness, controlled in vivo or in vitro studies have not been
conducted using these products. Thus, the goal of this
research was to investigate the effects of aqueous extracts
of Congaplex® and Immuplex® on the function of immor-
talized and primary cultured immune cells.
Methods
Materials
Plastic ware and general lab supplies that were used were
purchased from Fisher Scientific (Hampton, NH). Chem-
icals and reagents, including cell culture media, were pur-
chased from Sigma (St. Louis, MO), unless otherwise
indicated. Immuplex®  and Congaplex®  were obtained
from Standard Process, Inc. (Palmyra, WI).
Cell culture
Jurkat clone E6-1 and CEM cells were obtained from
ATCC (Manassas, VA) and cultured in RPMI (Sigma; St.
Louis, MO) supplemented with 100 units of penicillin,
100 μg/ml of streptomycin and 10% fetal bovine serum
(Atlanta Biologicals; Norcross, GA). Cultured cells were
maintained at 37°C in a humidified 5% CO2 atmosphere.
Cells were maintained between 105 and 106 cells/mL dur-
ing culturing. Jurkat and CEM cells used in the experi-
ments were between passage number 5 and 10.
Preparation of product extracts for cell culture 
experiments
Immuplex® and Congaplex® were extracted with Jurkat
growth media at a concentration of 62.5 mg/mL through
gentle shaking for 20 minutes. Samples were centrifuged
at 3,000 × g for 3 minutes to pellet unextracted material,
and the supernatant was used to treat cells. Congaplex® is
a dietary supplement that contains a combination of
bovine thymus extract, carrot, bovine bone, nutritional
yeast, defatted wheat germ, bovine adrenal, alfalfa juice,
oat flour, alfalfa flour, bovine kidney, veal bone, mush-
room, buckwheat herb juice, buckwheat seed, peanut
bran, soybean lecithin, soy tocopherols, carrot oil, cal-
cium lactate, gelatin, magnesium citrate, ascorbic acid,
calcium stearate and vitamin A palmitate. Immuplex® is a
dietary supplement that contains a combination of
bovine liver, veal bone extract, nutritional yeast, bovine
spleen, bovine thymus extract, ovine spleen, gelatin, zinc
liver chelate, ascorbic acid, iron liver chelate, chromium
yeast, copper liver chelate, selenium yeast, soy tocophe-
rols, pyridoxine hydrochloride, calcium stearate, vitamin
A palmitate, folic acid and cyanocobalamin.
Stimulation of cultured Jurkat and CEM cells
Both Jurkat and CEM cells were stimulated using a previ-
ously described protocol [32]. Cells were plated into 24-
well plates at a density of 1 × 106 cells per well in 0.5 mL
of growth media. Cells were incubated for 1 hour with the
extract from Immuplex® and Congaplex® at the indicated
concentrations, and then cells were activated with phyto-
hemagglutinin (PHA) and phorbol 12-myristate 13 ace-
tate (PMA) at concentrations of 5 μg/mL and 7.5 nM,
respectively.
Isolation and stimulation of human PBMCs
Peripheral blood mononuclear cells (PBMCs) were
obtained from five healthy male and five healthy female
subjects aged 23 to 46. This research was carried out in
compliance with the Helsinki Declaration as approved by
an institutional review board. Informed consent was
obtained from all subjects. PBMCs were isolated from
heparanized blood using Accuspin Histopaque (Sigma;
St. Louis, MO) according to the manufacturer's protocol.
Freshly isolated PMBCs were plated into 24-well plates at
a density of 5 × 105 cells per well in 0.5 mL of growth
media. Cells were then incubated for 1 hour with the
extract from Immuplex® and Congaplex® at 0.5 mg/mL,
then cells were activated with 20 μg/mL of PHA. Cells
were stimulated for 3 days with PHA before media was
assayed for cytokine concentrations.BMC Complementary and Alternative Medicine 2009, 9:51 http://www.biomedcentral.com/1472-6882/9/51
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Real time quantitative PCR
Four wells of cells were exposed to each treatment, as
described above. For each sample, cells were transferred
from the 24-well plate well into a microfuge tube and cen-
trifuged at 1,500 × g for 5 minutes. Media was removed
from the cell pellet, then cells were washed with 1 mL of
PBS. Cell pellet was then centrifuged again at 1,500 × g for
5 minutes, and PBS was removed before cell pellets were
stored at -80°C until RNA isolation. Total RNA was iso-
lated per manufacturer's protocol using the MagMAX™-96
Total RNA Isolation Kit (Ambion; Austin, TX). RNA con-
centrations were determined via a spectrophotometer
(NanoDrop; Wilmington, DE). cDNA was generated
using 1.5 μg of total RNA per 50 μL cDNA reaction with
the Applied Biosystems High Capacity cDNA Archive Kit,
following manufacturer's protocol (Foster City, CA).
Primer/probe kits for interleukin (IL)-2
(Hs99999150_m1), IL-8 (Hs99999034_m1), IL-10
(Hs99999035_m1, tumor necrosis factor (TNF)-α
(Hs00174128_m1), granulocyte monocyte colony stimu-
lating factor (GM-CSF) (Hs00171266_m1) and 18s ribos-
omal RNA (Hs99999901_s1) used for real time PCR
quantitation of RNA were obtained from Applied Biosys-
tems (Foster City, CA). Each treatment was represented by
four replicates and each PCR reaction was carried out in
duplicate. PCR was performed on an ABI 7300 Sequence
Detection System. Each 25 μL reaction contained 1 μL of
cDNA, 12.5 μL of 2 × Taqman Universal PCR Mastermix
(Applied Biosystems; Foster City, CA) and 1.25 μL of the
primer/probe reaction mixture (for the 18s ribosomal
RNA reaction the primer/probe mixture diluted 1:6 before
1.25 μL was added). All reactions were run with the fol-
lowing parameters: 2 minutes at 50°C then 10 minutes at
95°C followed by 40 cycles of 95°C for 15 seconds and
60°C for 1 minute. Fold changes between treatment
groups were then determined using the reaction efficiency
[33] and 18s ribosomal RNA as the reference gene: Ratio
= (Etarget)ΔCP target(control - sample)/(Eref)ΔCP ref(control -
sample).
Cell viability
Four wells of cells were exposed to each treatment, as
described above. Cell viability assay was performed as per
manufacturer's protocol after 24 hours of treatment
(Promega MultiTox-Fluor Multiplex Cytotoxicity Assay;
Madison, WI).
Multiplex quantitation of cytokines
Four wells of cells were exposed to each treatment as
described above. For each sample, cells were transferred
from the 24-well plate well into a microfuge tube and cen-
trifuged at 1,500 × g for 5 minutes. Media was removed
from the cell pellet and assayed for cytokine concentra-
tions using the Milliplex Human Cytokine Multiplex
Immunoassay Kit (Millipore; Billerica, MA). Quantitation
of GM-CSF, IFN-γ, IL-2, IL-4, IL-8, IL-10, IL-13 and TNF-α
in all cell types was performed as per the manufacturer's
protocol. Analysis was conducted on a Luminex 100
instrument (Luminex; Austin, TX) with Luminex LDS 1.7
SP2 data collection software. Calculation of cytokine con-
centrations was performed using cubic spline with Graph-
Pad Prism (San Diego, CA).
Statistical analysis
Each result is presented as mean ± standard deviation. The
statistical difference between treatments was determined
by analysis in GraphPad Prism (San Diego, CA) by one-
way analysis of variance (ANOVA). Non-normally distrib-
uted real-time PCR data (detailed in Figure 4) were trans-
formed using a natural log function prior to statistical
analysis.
Results
Activation of immortalized T lymphocytes with PHA and 
PMA results in peak elevation of cytokine RNA levels prior 
to peak concentrations of cytokine concentration in the 
media
CEM and Jurkat T lymphocytes were activated with PHA
and PMA as described in the Materials and Methods. After
0 (just prior to stimulation), 3, 6 and 24 hours following
stimulation media from the cells was collected for analysis
of the concentration of cytokines (Figure 1A, B) and cells
were harvested for analysis of cytokine RNA (Figure 1C,
D). The concentration of GM-CSF, IFN-γ, IL-2, IL-4, IL-8,
IL-10, IL-13 and TNF-α in the media of both Jurkat and
CEM cells was measured, and the results from the four
most abundant cytokines are shown in Figures 1A and 1B.
The concentrations of the cytokines in the media that are
not shown were all below 100 pg/mL at the 24 hour time-
point (data not shown). In both cell lines the peak con-
centrations were determined to be 24 hours after
stimulation for all of the cytokines measured. In compar-
ison, RNA was maximally expressed 6 hours and 3 hours
after stimulation for all four cytokines measured for CEM
and Jurkat cells, respectively.
Congaplex® and Immuplex® extracts affect PHA/PMA-
mediated cytokine production in immortalized T 
lymphocytes in opposing directions
Congaplex®  and Immuplex®  extracts, prepared as
described in Materials and Methods, were applied to cul-
tures of CEM and Jurkat T lymphocytes and cells were
incubated with the cells for 1 hour prior to stimulation
with PHA and PMA. Cells were treated with Congaplex®
and Immuplex® extracts at 0.1, 0.5, 1, 5 and 10 mg/mL and
the viability of the cells was assessed 24 hours after stim-
ulation (Figure 2). Congaplex® and Immuplex® signifi-
cantly reduced the viability of both cell lines at 5 and 10
mg/mL, and Congaplex® did not significantly affect cell
viability in either cell line at the 1 mg/mL concentrationBMC Complementary and Alternative Medicine 2009, 9:51 http://www.biomedcentral.com/1472-6882/9/51
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or lower. Immuplex® did not reduce Jurkat cell viability at
concentrations up to 1 mg/mL, however, there was signif-
icant reduction in CEM viability at 0.5 and 1 mg/mL.
The concentration of cytokines in the media was then
measured 24 hours after PMA and PHA stimulation, when
the concentration of cytokines in the media was at maxi-
mum levels (Figure 1A, B). Treatment of CEM cells with
Congaplex® resulted in a significant increase in IL-8 and
IL-10 concentrations in the media, while treatment of
these cells with Immuplex®  resulted in a significant
increase in IL-8 and significant decreases in the concentra-
tion of GM-CSF and IL-10 (Figure 3A). In CEM cells, TNF-
α concentration in the media was not significantly
affected by either Congaplex® or Immuplex®. Incubation
of Jurkat cells with Immuplex® resulted in a dose-depend-
ent increase in the concentration of IL-8 and a dose-
dependent decrease in the concentration of GM-CSF, IL-2
and TNF-α (Figure 3A). Incubation of Jurkat cells with
Congaplex® resulted in a dose-dependent increase in GM-
CSF, IL-2, IL-8 and TNF-α (Figure 3B). In the absence of
PMA/PHA stimulation Congaplex® and Immuplex® did
The timecourse of mRNA concentration and cytokine release into the media over the first 24 hours after stimulation with  PMA/PHA Figure 1
The timecourse of mRNA concentration and cytokine release into the media over the first 24 hours after 
stimulation with PMA/PHA. CEM (A, C) and Jurkat (B, D) cells were treated with PMA and PHA as described in Materials 
and Methods. Cells were harvested immediately before treatment (0 hour), and 3, 6 and 24 hours after treatment. Media was 
assayed for cytokine concentrations (A, B) using a multiplex bead assay. Cell pellets were assayed for mRNA corresponding to 
the same cytokines (C, D) using real-time PCR. For both cytokine and mRNA expression, data represents the average of three 
replicates ± standard deviation. Cytokine expression within each of the four genes (but not between genes) were compared by 
ANOVA with Tukey's post-hoc test. The mean concentrations of each individual cytokine were compared between each of the 
four timepoints. Means of groups that share a letter are not significantly different, whereas the means of any groups that do not 
share a letter are significantly different (p < 0.05). The concentrations of different cytokines were not compared to each other, 
thus display of significance only indicates differences in the concentration of the same cytokine at different timepoints. Data are 
representative of 3 independent experiments, using independent cell cultures, all of which produced similar results.
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not have significant effects on cytokine production (data
not shown). RNA was harvested from CEM and Jurkat T
lymphocytes after 6 and 3 hours of stimulation with PHA
and PMA, respectively, to achieve maximum expression
(Figure 1C, D). The effects of treatment with the 1 mg/mL
concentration of Immuplex®  and Congaplex®  on RNA
expression showed the same trend as seen in the cytokine
concentration in the media of both CEM and Jurkat cells
(Figure 4A, B).
Congaplex® and Immuplex® modulate cytokine release in 
PMBCs isolated from 10 different donors
Prior to analysis of cytokine expression from multiple
donors, PBMCs from a single donor were stimulated with
PHA and then 1, 2 and 3 days following stimulation
media from the cells was collected for analysis of the con-
centration of several cytokines (Figure 5). The media con-
centration of TNF-α, IL-2, IL-4, IL-10 and IFN-γ increased
on each day, reaching maximum concentrations of each
cytokine three days following stimulation.
PBMCs were isolated from 10 donors as described in the
Materials and Methods, then cells were treated with Con-
gaplex® and Immuplex® (0.5 mg/mL) for 1 hour before
being stimulated with PHA. Neither Congaplex®  nor
Immuplex® reduced the number of viable PBMCs at this
concentration (Figure 6). The same cytokines that were
measured in the immortalized cells (GM-CSF, IFN-γ, IL-2,
IL-4, IL-8, IL-10, IL-13 and TNF-α), were measured in the
media 3 days after stimulation (Figure 7). The media from
unstimulated PBMC cells had cytokine concentrations
below the level of detection with the exception of IL-8,
which had an average media concentration of 1262.2 pg/
mL ± 1089.0. The concentration of the other seven
Congaplex® and Immuplex® decrease the number of viable  CEM and Jurkat cells at concentrations of 5 and 10 mg/mL Figure 2
Congaplex® and Immuplex® decrease the number of 
viable CEM and Jurkat cells at concentrations of 5 
and 10 mg/mL. CEM and Jurkat cells were treated with 
Congaplex® and Immuplex® at the indicated concentrations 
for 1 hour prior to the addition of PMA and PHA. After 24 
hours of treatment with PMA and PHA the number of viable 
cells was measured as described in Materials and Methods. 
Data were normalized to the relative fluorescence units for 
the vehicle treatment of both CEM (black bars) and Jurkat 
(white bars) cells. Data represents the average of four repli-
cates ± standard deviation. * = significantly different from the 
vehicle treatment. Data are representative of 3 independent 
experiments, using independent cell cultures, all of which 
produced similar results.
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cytokines in the treatment media varied between donors
after 3 days of PHA stimulation (Table 1, Figure 7A), and
of these cytokines only four (IFN-γ, IL-13, GM-CSF and
TNF-α) had average media concentrations of greater than
100 pg/mL. Immuplex® significantly decreased expression
of IFN-γ and significantly increased IL-13 (Figure 7B), the
two most abundant T lymphocyte-specific cytokines.
Congaplex® trended to have a similar effect as Immuplex®
on the concentration of these two cytokines, although the
differences were not significant.
Discussion
The results of these experiments demonstrate that the
aqueous extract from Congaplex®  and Immuplex®  had
immunomodulatory effects in both immortalized cells
(CEM and Jurkat) as well as cultures of human primary
blood mononuclear cells (PBMCs). Congaplex®  and
Immuplex® had opposing effects on PMA/PHA-induced
activation of CEM and Jurkat cells, with Congaplex®
enhancing the stimulation and Immuplex® inhibiting the
stimulation (Figure 8). Alternatively, in the PBMCs the
effects were similar with both products, inhibiting pro-
duction of the most abundant Th1-related cytokine (IFN-
γ) and stimulating production of the most abundant Th2-
related cytokine (IL-13).
The results from the immortalized cell lines support the
use of Congaplex®  under conditions of infection or
increased chance of infection as a way to enhance the T
lymphocyte response that will protect the body from
infections, while Immuplex® would be used under healthy
conditions to suppress T lymphocyte-mediated inflamma-
tion that increases the risk of diseases such as Crohn's dis-
The aqueous extract from Immuplex® and Congaplex® alter  cytokine RNA expression following activation Figure 4
The aqueous extract from Immuplex® and Conga-
plex® alter cytokine RNA expression following activa-
tion. CEM (A) and Jurkat (B) cells were pre-treated the 
aqueous extract from Immuplex® or Congaplex® for one 
hour prior to treatment with PMA and PHA as described in 
Materials and Methods. CEM and Jurkat cells were harvested 
6 and 3 hours after PMA/PHA treatment, respectively, and 
cells were assayed for mRNA expression corresponding to 
cytokines using real-time PCR. Data are representative of 3 
independent experiments, using independent cell cultures, all 
of which produced similar results. Data represents the aver-
age of four replicates ± standard deviation. Data is presented 
as the percentage of cytokine concentration in cells treated 
with PMA and PHA in the absence of Immuplex® or Conga-
plex® treatment (vehicle). * = significantly higher than vehicle 
treatment. † = significantly lower than vehicle treatment.
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The timecourse of cytokine concentrations into the 
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multiplex bead assay. Data is presented as the percentage of 
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replicates ± standard deviation.
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ease, psoriasis vulgaris and rheumatoid arthritis.
Alternatively, the results from the PBMC experiments sug-
gest that Congaplex® and Immuplex® may both enhance
the Th2 response while suppressing the Th1 response.
Other natural products have been demonstrated to have
immunomodulatory effects, some of which enhance T
lymphocyte activation [34-36] while some suppress acti-
vation [37-39]. Congaplex® and Immuplex® may be work-
ing through the same or different mechanisms than these
other natural products, and therefore optimal in vivo activ-
ity could be accomplished through alternative therapies
that combine two or more of these supplements that have
demonstrated immunomodulatory properties.
These data have also demonstrated that the effects of Con-
gaplex® and Immuplex® were manifested at the level of
gene expression, as demonstrated by changes in both
cytokine levels (Figure 3) in the media as well as RNA lev-
els (Figure 4). Additionally, since the aqueous extract
from these supplements did not affect cytokine produc-
tion in the absence of the PMA/PHA stimulus, these sup-
plements are not working through a mechanism of direct
activation of these cells. This demonstrates that in the
immortalized CEM and Jurkat cells Congaplex®  and
Immuplex® are modulating the transcription of inflamma-
tory proteins.
The systematic increase and decrease in the expression of
inflammatory cytokines is critical for the control of the
inflammatory response [40,41]. Figure 1C and 1D dem-
onstrate a rapid (within 3 hours) upregulation of cytokine
RNA followed by a decline in mRNA expression levels by
24 hours. These data do not provide information about
the mechanism through which mRNA levels for these
Congaplex® and Immuplex® do not decrease the number of  viable PBMCs at 0.5 mg/mL Figure 6
Congaplex® and Immuplex® do not decrease the 
number of viable PBMCs at 0.5 mg/mL. PBMCs from a 
healthy volunteer were treated with Congaplex® and Immu-
plex® at 0.5 mg/mL for 1 hour prior to the addition of PHA. 
After 24 hours of treatment with PHA the number of viable 
cells was measured as described in Materials and Methods. 
Data were normalized to the relative fluorescence units for 
the vehicle treatment. Data represents the average of three 
replicates ± standard deviation. * = significantly different 
from the vehicle treatment.
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The aqueous extract from Immuplex® and Congaplex®  reduce cytokine release by human PBMCs in a dose-depend- ent manner Figure 7
The aqueous extract from Immuplex® and Conga-
plex® reduce cytokine release by human PBMCs in a 
dose-dependent manner. PBMCs from 10 healthy volun-
teers were pre-treated with the aqueous extract from Immu-
plex® or Congaplex® at 0.5 mg/mL for one hour prior to 
treatment with PHA as described in Materials and Methods. 
Cells were harvested 3 days after treatment and media was 
assayed for cytokine concentrations using a multiplex bead 
assay. A) A scatter plot shows the concentration of each 
cytokine in the media from each of the 10 donors after treat-
ment with PHA, in the absence of Congaplex® or Immuplex®. 
The average of all 10 donors is indicated as a horizontal bar ± 
standard deviation. For each donor, data represents the 
average of three replicates ± standard deviation. B) The 
effects of Congaplex® and Immuplex® on cytokine concentra-
tions in the media of cells treated with PHA. Data are 
expressed as the percentage difference from treatment with 
PHA and vehicle treatment. The data are presented as the 
average response of the PBMCs from the 10 donors ± stand-
ard deviation. * = significantly different from the vehicle 
treatment.
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cytokines are decreasing, but possible mechanisms
include decreases in transcription, transcriptional repres-
sion and/or a decrease in mRNA stability [42].
The differences of the response of immortalized cells and
PBMCs to Congaplex® and Immuplex® are likely due to the
differences between these experimental models. Immor-
talized cells such as the CEM and Jurkat cell lines have
been used extensively to study T cell function; however,
these cells are more closely related to leukemia cells than
healthy T lymphocytes, and therefore the relevance of
these results to the activity of healthy T lymphocytes may
be limited. Additionally, immortalized cells are a simpli-
fied model since cultures of these cells consist of only one
cell type, whereas PBMCs are a mixture of multiple cell
types. Therefore, interactions between cells in the
response of immune cells to Congaplex® and Immuplex®
would be overlooked in experiments using either CEM or
Jurkat cells.
However, the results from the immortalized CEM and Jur-
kat cells can have relevance to in vivo T lymphocyte func-
tion. Immortalized T lymphocytes have been used to
predict the in vivo immunomodulatory activity of many
natural products [43,44], including investigating the
mechanisms of T lymphocyte function [45,46]. The
results presented here show that the effect of Congaplex®
and Immuplex® are similar in two different T lymphocyte
cells lines (CEM and Jurkat). This strengthens the possibil-
ity that the results of these experiments are due to gener-
alized effects these extracts have on T lymphocytes rather
than effects to the specific immortalized cell line. Further-
more, while the comparison of these in vitro experiments
(with both immortalized and primary lymphocytes) sug-
gest that there may be complicated interactions occurring
in vivo, it also demonstrates the importance of using more
than one model to try to understand effects on materials
on a system as complex as the immune system.
Another source of complication in this experimental
model is the fact these dietary supplements are mixtures
of a number of different raw materials, and many of the
raw materials (such as alfalfa juice or buckwheat seed
powder) are also mixtures of countless nutrients and
other phytochemicals. This complexity of the materials,
unlike what is the case with pharmaceuticals or isolated
phytochemicals, is much more likely to have effects
through multiple mechanisms. This is also demonstrated
by the fact that foods, which are complex mixtures, have
been shown to affect immunity through a number of
mechanisms [16].
Furthermore, the extracts used in these experiments cer-
tainly underestimate the complexity of what an individual
will be exposed to when taking these supplements orally.
The bioavailability of the compounds in these supple-
ments, which will be affected by many things including
the digestive process, will be much different in vivo than
what the immune cells were exposed to in terms of an
aqueous extract in these experiments. Additionally, while
the extracts used in these experiments are likely to repre-
sent most of the polar compounds present in these sup-
plements, the non-polar compounds in the supplements
were not likely to be extracted. The non-polar compounds
in the supplements could directly modulate immune cell
function or work to affect how the polar compounds
affect immune cell function, however the experiments
described here do not address this possibility.
While these initial experiments have demonstrated that
Immuplex® and Congaplex® can have immunomodulatory
effects in vitro, in vivo studies would be required to deter-
mine what effects these products would have in the con-
text of the complexity of the whole organism where issues,
including bioavailability and cell-cell interactions, could
have important consequences. Furthermore, the data
from our ten donors also suggests that while the response
to Immuplex®  and Congaplex®  may differ significantly
between individuals. Certainly genetic differences and dif-
ferences between the abundance of different cell types
could have a large impact on how an individual might
respond to a supplement. Whether or not experiments
with PBMCs could be predictive of an individual's
response to these supplements would also be of interest.
Conclusions
Many traditional medicines are used in an attempt to
modulate immune function, however little evidence exists
supporting the activity of many of these medicines. This
report presents initial in vitro data supporting the anecdo-
tal evidence of the efficacy of Congaplex® and Immuplex®
in affecting immune function. The preliminary data pre-
sented here demonstrating that Congaplex® and Immu-
plex®  can have immunomodulatory effects in vitro
provides additional justification to conduct subsequent
animal and human trials that further investigate the activ-
ity of these supplements.
Table 1: Cytokine concentration in PHA-stimulated PBMCs on 
day 3 of culture
Range (pg/mL) Avg ± StDev (pg/mL)
IL-2 10 - 592 96 ± 177
IFN-γ 127 - 2667 1600 ± 929
IL-4 8 - 127 53 ± 44
IL-10 26 - 145 81 ± 41
IL-13 290 - 2178 1094 ± 686
GM-CSF 368 - 1181 685 ± 252
TNF-α 932 - 2078 1539 ± 386BMC Complementary and Alternative Medicine 2009, 9:51 http://www.biomedcentral.com/1472-6882/9/51
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